Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Hasselbalch, Hans Carl ^a   Thomassen, Mads ^b   Riley, Caroline Hasselbalch ^a   Kjær, Lasse ^a   Larsen, Thomas Stauffer ^b   Jensen, Morten K ^a   Bjerrum, Ole Weis ^a   Kruse, Torben A ^b   Skov, Vibe ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; CHEMOKINE RECEPTOR CXCR4; HYDROXYUREA; RECOMBINANT ALPHA INTERFERON; TRANSCRIPTION FACTOR NRF2; CXCR4 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; PLASMA PROTEIN;

ADULT; AGED; AKR1B1 GENE; ANTIOXIDATIVE DEFENCE GENE; ARTICLE; ATOX1 GENE; BLOOD EXAMINATION; CELL MIGRATION; COHORT ANALYSIS; CONTROLLED STUDY; CYBA GENE; DEFB122 GENE; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FEMALE; GENE; GENOMIC INSTABILITY; GPX8 GENE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; MYELOID METAPLASIA; NEOPLASM; NRF2 GENE; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; OXIDATIVE STRESS GENE; PATHOPHYSIOLOGY; POLYCYTHEMIA VERA; PRDX2 GENE; PRDX6 GENE; PROTEIN DEPLETION; PTGS1 GENE; SEPP1 GENE; SIRT2 GENE; STEM CELL EXPANSION; STEM CELL MOBILIZATION; STEM CELL NICHE; THROMBOCYTHEMIA; TRANSCRIPTION REGULATION; TTN GENE; UCP2 GENE; UPREGULATION; DENMARK; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; META ANALYSIS; METABOLISM; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; DENMARK; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NF-E2-RELATED FACTOR 2; RECEPTORS, CXCR4;

EID: 84911497964     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112786     Document Type: Article

References (51)

1. Campbell PJ, Green AR (2006) Mechanisms of disease: the myeloproliferative disorders. N Engl J Med 355(23): 2452-66.
2. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2007) The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 79(6): 508-15.
3. Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. (2012) Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 40(9): 771-80.
4. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, et al. (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin3. Haematologica 96(2): 315-8.
5. Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119(14): 3219-25.
6. Hasselbalch HC (2013) Chronic Inflammation as a Promoter of Mutagenesis in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. A Human Inflammation Model for Cancer Development? Leuk Res 37(2): 214-20.
7. Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24(2): 133-45.
8. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118(25): 6515-20.
9. Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, et al. (2013) A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression. Leukemia 27(11): 2187-95.
10. Kim J, Cha YN, Surh Y-JYJ (2010) A protective role of nuclear factor-erythroid 2- related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 690: 12-23.
11. Tsai JJ, Dudakov JA, Takahashi K, Shieh JH, Velardi E, et al. (2013) Nrf2 regulates haematopoietic stem cell function. Nature Cell Biology 15(3): 309-316.
12. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, et al. (2001) Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98(12): 3249-55.
13. Ihaka R, Gentleman R (1996) R: A language for data analysis and graphics. J Comp Graph Stat 5: 299-314.
14. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
15. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
16. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
17. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, et al. (2011) Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 87(1): 54-60.
18. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, et al. (2012) Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res 36(11): 1387-92.
19. Grivennikov SI, Greten FR, Karin M (2010). Immunity, inflammation, and cancer. Cell 140: 883-99.
20. Ferguson LR (2010) Chronic inflammation and mutagenesis. Mutat Res 690: 3-11.
21. Yahata T, Takanashi T, Muguruma Y, Ibrahim AA, Matsuzawa H, et al (2011) Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. Blood 118(11): 2941-50.
22. Shao L, Li H, Senthil K. Pazhanisamy SK, Meng A, et al. (2011) Reactive oxygen species and hematopoietic stem cell senescence. Int J Hematol 94: 24-32.
23. Austin C (2009) Does oxidative damage contribute to the generation of leukemia? Leuk Res 33: 1297.
24. Hole PS, Darley RL, Tonks A (2011) Do reactive oxygen species play a role in myeloid leukemias? Blood 2;117(22): 5816-5826.
25. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, et al. (2011) Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118(24): 6392-8.
26. Hermouet S, Vilaine M (2011) The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica 96(11): 1575-9.
27. Merchant AA, Singh A, Matsui W, Biswal S (2011) The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood 118(25): 6572-9.
28. Ghaffari S (2008) Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxidants & Redox Signaling 10(11): 1923-1940.
29. Naka K, Muraguchi T, Hoshii T, Hirao A (2008) Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxidants & Redox Signaling 10(11): 1883-1894.
30. Jang YY, Sharkis SJ (2007) A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 110: 3056-63.
31. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8): 1343-74.
32. Moll NM, Ransohoff RM (2010) CXCL12 and CXCR4 in bone marrow physiology. Expert Rev Hematol 3(3): 315-22.
33. Nie Y, Han YC, Zou YR (2008) CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 205: 777-83.
34. Tzeng YS, Li H, Kang YL, Chen WC, Cheng WC, et al. (2011) Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood 117: 429-39.
35. Rosti V, Massa M, Vannucchi AM, Bergamaschi G, Campanelli R, et al. (2007) The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 38(3): 280-6.
36. Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, et al. (2008) Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol 36(2): 158-71.
37. Cencioni C, Spallotta F, Martelli F, Valente S, Mai A, et al. (2013) Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int J Mol Sci 14(9): 17643-63.
38. Pérez C, Pascual M, Martin-Subero JI, Bellosillo B, Segura V, et al. (2013) Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica 98(9): 1414-20.
39. Balkwill F (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13(2): 135-141.
40. Hasselbalch HC (2013) A Role of NF-E2 in Chronic Inflammation and Clonal Evolution in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis? Leuk Res 38(2): 263-6.
41. Silver RT, Kiladjian JJ, Hasselbalch HC (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol 6(1): 49-58.
42. Di Bona D, Cippitelli M, Fionda C, Cammà C, Licata A, et al. (2006) Oxidative stress inhibits IFN-alpha-induced antiviral gene expression by blocking the JAKSTAT pathway. J Hepatol 45(2): 271-9.
43. Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, et al. (2011) Increase in circulating CD+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myelopoliferative neoplasms during treatment with IFN-alpha2. Blood 118(8): 2170-3.
44. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE at al. (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11(12): 1306-13.
45. Tothova Z, Gilliland DG (2007) FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 1(2): 140-52.
46. Barzilai A, Rotman G, Shiloh Y (2002) ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 1(1): 3-25.
47. Rodrigues RM, Fernandez AF, Fraga MF (2013) Role of sirtuins in stem cell differentiation. Genes Cancer 4(3-4): 105-11.
48. Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, et al. (2012) Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 53(1): 123-9.
49. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, et al. (2010) ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. EMBO J 29: 4118-4131.
50. Hasselbalch HC, Skov V, Larsen TS, Thomassen M, Riley CH, et al. (2011) High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis. Leuk Res 35(10): 1330-4.
51. Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, et al. (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia,polycythemia vera and myelofibrosis. Leuk Lymphoma 54(10): 2269-73.